Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 801–900 of 1,001

Exploration of tumor growth regression of quinoa and chia oil nanocapsules via the control of PIK3CA and MYC expression, anti-inflammation and cell proliferation inhibition, and their hepatorenal safety in rat breast cancer model
Makawy, A. I. E., Abdel‐Aziem, S. H., Mohammed, S. E., Ibrahim, F. M., EL-Kader, H. A. A., Sharaf, H. A., Youssef, D. A., & Mabrouk, D. M. (2024) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-023-01161-3 · Cited by 23
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
Liu, Y., Li, C., Liu, H., & Tan, S. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01494-1 · Cited by 26
Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways
Mohanty, P., Pande, B., Acharya, R. K., Bhaskar, L. V., & Verma, H. K. (2024) · Diseases · doi:10.3390/diseases12050093 · Cited by 20
Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell lung cancer by promoting endoplasmic reticulum stress and mitochondrial dysfunction
Xu, Z., Shi, Y., Zhu, L., Luo, J.-H., Hu, Q., Jiang, S., Xiao, M., Jiang, X., Wang, H., Xu, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217075 · Cited by 21
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
Sigawi, T., Gelman, R., Maimon, O., Yossef, A., Hemed, N., Agus, S., Berg, M., Ilan, Y., & Popovtzer, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1426426 · Cited by 21
Next‐Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions
Fletcher, N. L., Kempe, K., & Thurecht, K. J. (2020) · Macromolecular Rapid Communications · doi:10.1002/marc.202000319 · Cited by 21
The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer
Zhao, G., Zhou, A., Li, X., Zhu, S., Wang, Y., Zhang, S., & Li, P. (2021) · Genes · doi:10.3390/genes12010073 · Cited by 22
Challenges and material innovations in drug delivery to central nervous system tumors
Gong, Z., Zhou, D., Wu, D., Han, Y., Yu, H. Q., Shen, H., Feng, W., Hou, L., Chen, Y., & Xu, T. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123180 · Cited by 23
A narrative review: Ultrasound-Assisted drug delivery: Improving treatments via multiple mechanisms
Tao, W., Lai, Y., Zhou, X., Yang, G., Wu, P., & Yuan, L. (2025) · Ultrasonics · doi:10.1016/j.ultras.2025.107611 · Cited by 20
Artificial intelligence and anti-cancer drugs' response
Long, X., Sun, K., Lai, S., Liu, Y., Su, J., Chen, W., Liu, R., He, X., Zhao, S., & Huang, K. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.009 · Cited by 21
Recent advances of smart acid‐responsive gold nanoparticles in tumor therapy
Zhang, Y., Yang, L., Yang, C., & Liu, J. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1619 · Cited by 22
Potential of Bioactive Food Components against Gastric Cancer: Insights into Molecular Mechanism and Therapeutic Targets
Kang, S. Y., Hwang, D., Shin, S., Park, J., Kim, M., Rahman, M. H., Rahman, M. A., Ko, S., & Kim, B. (2021) · Cancers · doi:10.3390/cancers13184502 · Cited by 20
Blocking iASPP/Nrf2/M-CSF axis improves anti-cancer effect of chemotherapy-induced senescence by attenuating M2 polarization
Liu, H., Zhao, D. H., Li, H., Zhang, W., Lin, Q., Wang, X., Zheng, S., Zhang, L., Li, L., Hu, S., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04611-4 · Cited by 21
Exosomes in urological diseases - Biological functions and clinical applications
Song, Q., Yu, H., Han, J., Lv, J., Lv, Q., & Yang, H. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215809 · Cited by 21
Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer
Elakad, O., Häupl, B., Labitzky, V., Yao, S., Küffer, S., von Hammerstein-Equord, A. F., Danner, B. C., Jücker, M., Urlaub, H., Lange, T., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00296-2 · Cited by 20
Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors
Khan, M. M., & Torchilin, V. P. (2022) · Cancers · doi:10.3390/cancers14174123 · Cited by 20
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression
Farnsworth, D., Inoue, Y., Johnson, F. D., de Rappard-Yuswack, G., Lu, D., Shi, R., Ma, L. I. J., Mattar, M. S., Somwar, R., Ladanyi, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00328-x · Cited by 21
Association of CYP24A1 with survival and drug resistance in clinical cancer patients: a meta-analysis
Zeng, R., Li, H., Jia, L., Lee, S. H., Jiang, R., Zhang, Y., Hu, X., Ye, T., Wang, X., Yan, X., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10369-x · Cited by 20
A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer
Ramisetty, S. K., Kulkarni, P., Bhattacharya, S., Nam, A., Singhal, S. S., Guo, L., Mirzapoiazova, T., Mambetsariev, B., Mittan, S., Malhotra, J. D., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020599 · Cited by 22
Aptamer-conjugated carbon nanotubes or graphene for targeted cancer therapy and diagnosis
Barani, M., Khatami, M., Behnam, B., Rajendram, R., Kesharwani, P., & Sahebkar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85881-6.00018-x · Cited by 20
Shining the light on mesenchymal stem cell-derived exosomes in breast cancer
Al‐Awsi, G. R. L., Alsaikhan, F., Margiana, R., Ahmad, I., Patra, I., Najm, M. A. A., Yasin, G., Rasulova, I., Hammid, A. T., Kzar, H. H., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03245-3 · Cited by 21
ITGB3 promotes cisplatin resistance in osteosarcoma tumors
Li, Q., Chen, G., Jiang, H., Dai, H., Li, D., Zhu, K., Zhang, K., Shen, H., Xu, H., & Li, S. (2023) · Cancer Medicine · doi:10.1002/cam4.5585 · Cited by 19
LncRNA CASC19: a novel oncogene involved in human cancer
Wang, S., Qiao, C., Fang, R., Yang, S., Zhao, G., Liu, S., & Li, P. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03165-x · Cited by 20
Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies
Younes, S. N., Ismail, M. A., Al‐Jurf, R., Ziyada, A., Nasrallah, G. K., Abdulrouf, P. V., Nagy, M., Zayed, H., Farrell, T. J., Sorio, C., et al. (2023) · Hematology · doi:10.1080/16078454.2023.2196866 · Cited by 21
Forces at play: exploring factors affecting the cancer metastasis
Riaz, F., Zhang, J., & Pan, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1274474 · Cited by 23
Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome
Broghammer, F., Korovina, I., Gouda, M., Celotti, M., van Es, J. H., Lange, I., Brunner, C., Mircetic, J., Coppes, R. P., Gires, O., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01954-8 · Cited by 25
Peptides as innovative strategies to combat drug resistance in cancer therapy
Lamb, H., Benfield, A. H., & Henriques, S. T. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104206 · Cited by 20
l -Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy
Guo, W., Chen, Z., Tan, L., Wu, Q., Ren, X., Fu, C., Du, Y., Ren, J., & Meng, X. (2020) · Chemical Communications · doi:10.1039/c9cc09712k · Cited by 20
Parallel evolution of polymer chemistry and immunology: Integrating mechanistic biology with materials design
Sadtler, K., Collins, J., Byrne, J. D., & Langer, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.021 · Cited by 20
Pterostilbene inhibits gallbladder cancer progression by suppressing the PI3K/Akt pathway
Tong, C., Wang, Y., Li, J., Cen, W., Zhang, W., Zhu, Z., Yu, J., & Lu, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-83924-4 · Cited by 20
Practicable Applications of Aggregation‐Induced Emission with Biomedical Perspective
Wang, Y., Xia, B., Huang, Q., Luo, T., Zhang, Y., Timashev, P. S., Guo, W., Li, F., & Liang, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100945 · Cited by 21
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Willey, J. C., Morrison, T. B., Austermiller, B., Crawford, E. L., Craig, D. J., Blomquist, T. M., Jones, W. D., Wali, A., LoCoco, J. S., Haseley, N., et al. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100106 · Cited by 21
Utilizing the metal coordination and supramolecular chemistry of macrocycles to tackle medicinal issues
Redshaw, C. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216147 · Cited by 18
Role of the USP family in autophagy regulation and cancer progression
Liu, C., Yuan, Y., Zhan, Y., Zou, M., Wu, L., Zhang, C., Chen, B., Zeng, H., Yang, R., Hu, T., et al. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02095-z · Cited by 21
Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies
Giri, S., Lamichhane, G., Pandey, J., Khadayat, R., Sindhu, K. C., Devkota, H. P., & Khadka, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072923 · Cited by 22
Cancer therapy resistance from a spatial‐omics perspective
Zhang, Y., Yang, C., Chen, X., Wu, L. L., Yuan, Z., Zhang, F., & Qian, B. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70396 · Cited by 19
Mechanisms of resistance to antibody-drug conjugates in breast cancer
Çerçi, B., Saatci, Ö., Basik, M., & Şahin, Ö. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101353 · Cited by 19
A multifunctional nano-delivery system enhances the chemo- co -phototherapy of tumor multidrug resistance via mitochondrial-targeting and inhibiting P-glycoprotein-mediated efflux
Zhao, R., Ning, X., Wang, M., Yu, A., & Wang, Y. (2021) · Journal of Materials Chemistry B · doi:10.1039/d1tb01658j · Cited by 19
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
Solis, R. N., Silverman, D. A., & Birkeland, A. C. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00942-8 · Cited by 19
Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase
Min, H., Lee, H. J., Suh, Y., Pei, H., Kwon, H.-J., Jang, H.-J., Yun, H. J., Moon, H., & Lee, H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01843-1 · Cited by 19
Wang resin catalyzed sonochemical synthesis of dihydropyrano[2,3-c]pyrazole derivatives and their interactions with SIRT1
Kondabanthini, S., Katari, N. K., Srimannarayana, M., Gundla, R., Kapavarapu, R., & Pal, M. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133527 · Cited by 19
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
A model for the intrinsic limit of cancer therapy: Duality of treatment-induced cell death and treatment-induced stemness
Angelini, E., Wang, Y., Zhou, J., Qian, H., & Huang, S. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010319 · Cited by 20
PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9
Sun, X., Li, K., Aryal, U. K., Li, B., & Yokota, H. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.08.003 · Cited by 19
In Vitro and In Vivo Biological Activity of Ruthenium 1,10-Phenanthroline-5,6-dione Arene Complexes
Lenis-Rojas, O. A., Roma‐Rodrigues, C., Carvalho, B. G., Cabezas‐Sainz, P., Vila, S. F., Sanchez, L. E., Baptista, P. V., Fernandes, A. R., & Royo, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113594 · Cited by 19
Enhanced Cancer Imaging and Chemo‐Photothermal Combination Therapy by Cancer‐Targeting Bismuth‐Based Nanoparticles
Bao, Q., Zhang, Y., Liu, X., Yang, T., Hui, Y., Yang, M., & Mao, C. (2023) · Advanced Optical Materials · doi:10.1002/adom.202201482 · Cited by 19
Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer
Zhang, D., Jia, T., Chen, X., Jiang, H., Guo, T., Dong, J., Zeng, H., Wang, Y., & Yuan, Y. G. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13840 · Cited by 19
A View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0776 · Cited by 21
The Interplay between Microbiota and Chemotherapy-Derived Metabolites in Breast Cancer
Plaza‐Díaz, J., & Álvarez‐Mercado, A. I. (2023) · Metabolites · doi:10.3390/metabo13060703 · Cited by 20
Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
Hassel, J. C., Zimmer, L., Sickmann, T., Eigentler, T., Meier, F. E., Mohr, P., Pukrop, T., Roesch, A., Vordermark, D., Wendl, C. M., et al. (2023) · Cancers · doi:10.3390/cancers15133448 · Cited by 21
Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
Devarajan, R., Izzi, V., Peltoketo, H., Rask, G., Kauppila, S., Väisänen, M., Ruotsalainen, H. J., Martínez-Nieto, G., Karppinen, S., Väisänen, T., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci159181 · Cited by 19
J-Aggregation induced NIR-II fluorescence: an aza-BODIPY luminogen for efficient phototheranostics
Yang, N., Song, S., Akhtar, M. H., Liu, C., Yao, L., Yu, J., Li, Y., Li, Q., He, D. D., & Yu, C. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01280h · Cited by 19
Supramolecular host-guest nanosystems for overcoming cancer drug resistance
Wu, S., Yan, M., Liang, M., Yang, W., Chen, J., & Zhou, J. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.77 · Cited by 20
A comprehensive review of the anticancer effects of decursin
Chu, Y., Yuan, Q., Jiang, H., Wu, L., Xie, Y., Zhang, X., & Li, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1303412 · Cited by 19
Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations
Hao, B., Ma, K., Xu, J.-Y., Fan, R., Zhao, W.-S., Jia, X., Zhai, L., Lee, S., Xie, D., & Tan, M. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01236-5 · Cited by 23
Role of Exosomes in Cancer and Aptamer-Modified Exosomes as a Promising Platform for Cancer Targeted Therapy
Wu, Y., Cao, Y., Chen, L., Lai, X., Zhang, S., & Wang, S. (2024) · Biological Procedures Online · doi:10.1186/s12575-024-00245-2 · Cited by 20
Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs
Wang, Y.-J., Lin, P., Hsieh, S., Kirankumar, R., Lin, H., Lin, H., Chen, Y.-T., Wu, H.-M., & Hsieh, S. (2021) · Materials · doi:10.3390/ma14081824 · Cited by 19
Cyclodextrin-Based Hybrid Polymeric Complex to Overcome Dual Drug Resistance Mechanisms for Cancer Therapy
Ke, L., Li, Z., Fan, X., Loh, X. J., Cheng, H., Wu, Y., & Li, Z. (2021) · Polymers · doi:10.3390/polym13081254 · Cited by 20
Stimuli-responsive nanomaterials for cancer treatment: boundaries, opportunities and applications
Lafuente‐Gómez, N., Latorre, A., Milán-Rois, P., Rodríguez-Díaz, C., & Somoza, Á. (2021) · Chemical Communications · doi:10.1039/d1cc05056g · Cited by 19
CTR-DB 2.0: an updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers
Jiang, J., Ma, Y., Yang, L., Ma, S., Yu, Z., Ren, X., Kong, X., Zhang, X., Li, D., & Liu, Z. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae993 · Cited by 19
Acceptor Elongation Boosted Intersystem Crossing Affords Efficient NIR Type‐I and AIE‐Active Photosensitizers for Targeting Ferroptosis‐Based Cancer Therapy
Zhu, Y., Zhang, R., Cai, X., Zhang, L., Bo, W., Tan, H., Zhou, K., Wang, H., Liu, Y., Luo, Y., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404505 · Cited by 18
Living Microalgae‐Based Magnetic Microrobots for Calcium Overload and Photodynamic Synergetic Cancer Therapy
Jiang, S., Hao, B., Song, X., Jiang, Y., Guo, J., Wang, Y., Wang, Q., Wang, X., Xu, T., Wu, X., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403866 · Cited by 18
Provoking Lysosome Disruption via In Situ Engineered Double-Network Assemblies for Targeted Cancer Cell Death
Zhang, S., Lv, J., Cheng, X., Chen, K., Wei, Q., Gong, X., Wei, X., Huang, X., Du, E., Xiu, L., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c00268 · Cited by 18
Halofuginone Disrupted Collagen Deposition via mTOR‐eIF2α‐ATF4 Axis to Enhance Chemosensitivity in Ovarian Cancer
Li, W., Wu, Y., Zhang, Y., Gao, W., Li, X., Luo, H., Lu, M., Liu, Z., & Luo, A. (2025) · Advanced Science · doi:10.1002/advs.202416523 · Cited by 22
Dual membrane receptor degradation via folate receptor targeting chimera
Wang, Z., Li, Z., Hogstrom, J. M., Inuzuka, H., Jing, R., Yan, P., Hou, T., Qi, Y., Huang, D., Wang, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63882-5 · Cited by 18
The molecular mechanisms of mitochondrial dynamics and mitophagy and their complex association with cancer drug resistance
Zhao, Z., Ren, Y., Yuan, M., Liu, G., & Sun, J. P. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07078-x · Cited by 23
Emerging Role of Chimeric RNAs in Cell Plasticity and Adaptive Evolution of Cancer Cells
Mukherjee, S., Heng, H. H., & Frenkel‐Morgenstern, M. (2021) · Cancers · doi:10.3390/cancers13174328 · Cited by 19
Apoptotic and antioxidant effects in HCT-116 colorectal carcinoma cells by a spiro-acridine compound, AMTAC-06
Duarte, S. S., Silva, D. K. F., Lisboa, T. M. H., Gouveia, R. G., de Andrade, C. C. N., de Sousa, V. M., Ferreira, R. C., de Moura, R. O., Gomes, J. N. S., da Silva, P. M., et al. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00357-0 · Cited by 18
Circular RNA hsa_circ_0011298 enhances Taxol resistance of non‐small cell lung cancer by regulating miR‐486‐3p/CRABP2 axis
Wu, Y., Xie, J., Wang, H., Hou, S., & Feng, J. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24408 · Cited by 18
Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer
Lee, S. Y., Yang, W., Kim, D. K., Kim, H., Shin, M., Choi, K. U., Suh, D. S., Kim, Y. H., Hwang, T.-H., & Kim, J. H. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.04.006 · Cited by 18
Loss of cell division cycle‑associated 5 promotes cell apoptosis by activating DNA damage response in clear cell renal cell carcinoma
Huang, X., Huang, Y., Lv, Z., Wang, T., Feng, H., Wang, H., Du, S., Wu, S., Shen, D., Wang, C., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5377 · Cited by 18
Polymeric Carriers for Delivery of RNA Cancer Therapeutics
Mirón‐Barroso, S., Correia, J. S., Frampton, A. E., Lythgoe, M. P., Clark, J., Tookman, L. A., Ottaviani, S., Castellano, L., Porter, A. E., Georgiou, T. K., et al. (2022) · Non-Coding RNA · doi:10.3390/ncrna8040058 · Cited by 18
A life history model of the ecological and evolutionary dynamics of polyaneuploid cancer cells
Bukkuri, A., Pienta, K. J., Austin, R. H., Hammarlund, E. U., Amend, S. R., & Brown, J. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-18137-4 · Cited by 18
Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold—A Short Review of Most Recent Studies 2013–2022
Kozyra, P., & Pitucha, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168874 · Cited by 21
Halofuginone for cancer treatment: A systematic review of efficacy and molecular mechanisms
Mi, L., Zhang, Y., Su, A., Tang, M., Xing, Z., He, T., Wu, W., & Li, Z. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105237 · Cited by 18
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
Wirth, A.-K., Wange, L. E., Vosberg, S., Henrich, K., Rausch, C. R., Özdemir, E. Z., Zeller, C., Richter, D., Feuchtinger, T. F., Kaller, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01726-7 · Cited by 21
Modelling the spatial dynamics of oncolytic virotherapy in the presence of virus-resistant tumour cells
Bhatt, D., Janzen, T., Daemen, T., & Weissing, F. J. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010076 · Cited by 19
Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro
Wilke, N. L., Burmeister, H., Frias, C., Ott, I., & Prokop, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020952 · Cited by 18
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
Pandey, G. K., Landman, N., Neikes, H. K., Hulsman, D., Lieftink, C., Beijersbergen, R. L., Kolluri, K. K., Janes, S. M., Vermeulen, M., Badhai, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100915 · Cited by 18
Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype
Nisticò, N., Aloisio, A., Lupia, A., Zimbo, A. M., Mimmi, S., Maisano, D., Russo, R., Marino, F., Scalise, M., Chiarella, E., et al. (2023) · Cells · doi:10.3390/cells12071078 · Cited by 18
Single-sized N-functionality graphene quantum dot in tunable dual-modality near infrared–I/II illumination detection and photodynamic therapy under multiphoton nonlinear excitation
Kuo, W., Chang, C.-Y., Chuang, H.-Y., Su, P., Wang, J., Wu, P., Kao, H.-F., Tseng, S.-W., Lin, S.-H., Lin, Y., et al. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115648 · Cited by 18
Improvement of the effectiveness of sonodynamic therapy: by optimizing components and combination with other treatments
Wang, X., Xu, X., Yang, Z., Xu, X., Han, S., & Zhang, H. (2023) · Biomaterials Science · doi:10.1039/d3bm00738c · Cited by 18
Subcutaneous Rapid Dissolution Microneedle Patch Integrated with CuO 2 and Disulfiram for Augmented Antimelanoma Efficacy through Multimodal Synergy of Photothermal Therapy, Chemodynamic Therapy, and Chemotherapy
Yu, S., Ni, H., Xu, X., Cai, Y., Feng, J., & Zhang, J. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00867 · Cited by 18
Cancer nanomedicine: emergence, expansion, and expectations
Kizhakkanoodan, K. S., Rallapalli, Y., Praveena, J., Acharya, S., & Guru, B. R. (2023) · SN Applied Sciences · doi:10.1007/s42452-023-05593-4 · Cited by 19
Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer
Garbuzenko, O. B., Sapiezynski, J., Girda, E., Rodríguez-Rodríguez, L., & Minko, T. (2024) · Small · doi:10.1002/smll.202307462 · Cited by 18
Optimizing cancer therapy: a review of the multifaceted effects of metronomic chemotherapy
Basar, O. Y., Mohammed, S. G. A. A., Qoronfleh, M. W., & Acar, A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1369597 · Cited by 18
Harnessing machine learning potential for personalised drug design and overcoming drug resistance
Hakami, M. A. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2365934 · Cited by 20
S. glabra exerts anti-lung cancer effects by inducing ferroptosis and anticancer immunity
Liu, S., Zhang, L., Ding, K., Zeng, B., Li, B., Zhou, J., Li, J., Wang, J., Zhang, H., Sun, R., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155981 · Cited by 18
The Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review
Jones, S. W., Ball, A. L., Chadwick, A. E., & Alfirevic, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.698825 · Cited by 18
Targeting Oncogene Promoters and Ribosomal RNA Biogenesis by G-Quadruplex Binding Ligands Translate to Anticancer Activity
Suseela, Y. V., Sengupta, P., Roychowdhury, T., Panda, S., Talukdar, S., Chattopadhyay, S., Chatterjee, S., & Govindaraju, T. (2021) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.1c00039 · Cited by 18
Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerPreprint
Safonov, A. M., Marra, A., Bandlamudi, C., O’Leary, B., Wubbenhorst, B. S., Ferraro, E., Moiso, E., Lee, M., An, J. A.-R., Donoghue, M. T. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.05.578934 · Cited by 18
Self-assembled phthalocyanine-based nano-photosensitizers in photodynamic therapy for hypoxic tumors
He, L., & Ma, D. (2024) · Materials Chemistry Frontiers · doi:10.1039/d4qm00602j · Cited by 17
Virus-inspired biogenic delivery system for advancing cancer therapy
Sun, D., Hao, L., Mu, Q., Chu, C., Liu, G., & Liu, C. (2025) · Biomedical Technology · doi:10.1016/j.bmt.2025.100069 · Cited by 17
Aptamer-based applications in delivering cancer gene therapies and beyond: state of the art and the missing links to clinical translation
Coppola, G., Cennamo, F., Ciccone, G., Ibba, M. L., Ruscio, A. D., Vito, A. D., Esposito, C. L., & Catuogno, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115639 · Cited by 17
Designing Protein-Based Nanoparticles for Therapeutic Applications
Cui, J., Wang, K., Wu, Z., Sun, W., Gao, T., Shen, X., Wang, W., Cao, Y., & Xue, B. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c10918 · Cited by 18
Mass Spectrometry Guided Discovery and Design of Novel Asperphenamate Analogs From Penicillium astrolabium Reveals an Extraordinary NRPS Flexibility
Subko, K., Wang, X., Nielsen, F. H., Isbrandt, T., Gotfredsen, C. H., Ramos, M. C., Mackenzie, T. A., Vicente, F., Genilloud, O., Frisvad, J. C., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.618730 · Cited by 17
Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling
Salama, Y., Jaradat, N. A., Hattori, K., & Heissig, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158151 · Cited by 17
Ultrasound assisted Cu-catalyzed decarbonylative Sonogashira coupling-cyclization strategy: Synthesis and evaluation of 3-heteroarylmethylene isoindolin-1-ones against SIRT1
Ganapathisivaraja, P., Rao, G. V., Abburi, R., Tej, M. B., Praneeth, M. S., Kapavarapu, R., Rao, M. V. B., & Pal, M. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131788 · Cited by 17
3D microgels to quantify tumor cell properties and therapy response dynamics
Wu, N. C., Cadavid, J. L., Tan, X., Latour, S., Scaini, S., Makhijani, P., McGaha, T. L., Ailles, L., & McGuigan, A. P. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121417 · Cited by 16
The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response
Masud, M. A., Kim, J., Pan, C., & Kim, E. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009919 · Cited by 18

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks